Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Arvinas, Inc. (ARVN : NSDQ)

• Company Description    Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States. Number of Employees: 246

• Price / Volume Information    Yesterday's Closing Price: $9.09 Daily Weekly Monthly 20 Day Moving Average: 977,722 shares Shares Outstanding: 64.52 (millions) Market Capitalization: $586.50 (millions) Beta: 1.79 52 Week High: $14.51 52 Week Low: $6.06 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -12.76% -17.02% 12 Week -32.06% -37.20% Year To Date -23.36% -29.46%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5 SCIENCE PARK 395 WINCHESTER AVENUE - NEW HAVEN,CT 06511 USA ph: 203-535-1456 fax: - ir@arvinas.com http://www.arvinas.com

• General Corporate Information    Officers Randy Teel - PresidentChief Executive Officer and Director Briggs Morrison - Chairman Andrew Saik - Chief Financial Officer and Treasurer David K. Loomis - Vice President and Chief Accounting Officer Sunil Agarwal - Director Peer Information Arvinas, Inc. (CORR.) Arvinas, Inc. (RSPI) Arvinas, Inc. (CGXP) Arvinas, Inc. (BGEN) Arvinas, Inc. (GTBP) Arvinas, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 04335A105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/05/26 Share - Related Items Shares Outstanding: 64.52 Most Recent Split Date: (:1) Beta: 1.79 Market Capitalization: $586.50 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.23 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.85 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.52 Price/Cash Flow: - Price / Sales: 6.56 EPS Growth vs. Year Ago Period: -178.95% vs. Previous Quarter: 18.18% Sales Growth vs. Year Ago Period: -91.74% vs. Previous Quarter: 64.21% ROE 03/31/26 - -44.38 12/31/25 - -14.25 09/30/25 - -9.77 ROA 03/31/26 - -28.38 12/31/25 - -9.31 09/30/25 - -6.08 Current Ratio 03/31/26 - 5.44 12/31/25 - 4.92 09/30/25 - 5.70 Quick Ratio 03/31/26 - 5.44 12/31/25 - 4.92 09/30/25 - 5.70 Operating Margin 03/31/26 - -247.54 12/31/25 - -30.77 09/30/25 - -18.73 Net Margin 03/31/26 - -247.54 12/31/25 - -30.77 09/30/25 - -18.73 Pre-Tax Margin 03/31/26 - -247.32 12/31/25 - -30.66 09/30/25 - -18.76 Book Value 03/31/26 - 5.99 12/31/25 - 6.76 09/30/25 - 7.69 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.08 12/31/25 - 0.09 09/30/25 - 0.07

Powered by Zacks Investment Research ©